Trials / Conditions / Resectable Head and Neck Squamous Cell Carcinoma

Resectable Head and Neck Squamous Cell Carcinoma

8 registered clinical trials studyying Resectable Head and Neck Squamous Cell Carcinoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma NCT07492914	West China Hospital	Phase 2
Recruiting	Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negativ NCT06997094	Mayo Clinic	Phase 1
Recruiting	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer NCT07094685	University of Michigan Rogel Cancer Center	Phase 2
Recruiting	Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC NCT05726370	Dana-Farber Cancer Institute	Phase 2
Unknown	Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcino NCT06235918	Xiang Lu	Phase 2
Recruiting	Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer NCT04754321	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers NCT05120947	Medical College of Wisconsin	N/A